Retinal Vein Occlusion – Drugs in Development, 2021

Global Markets Direct’s, ‘Retinal Vein Occlusion – Drugs in Development, 2021’, provides an overview of the Retinal Vein Occlusion pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinal Vein Occlusion, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinal Vein Occlusion and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Retinal Vein Occlusion

– The report reviews pipeline therapeutics for Retinal Vein Occlusion by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Retinal Vein Occlusion therapeutics and enlists all their major and minor projects

– The report assesses Retinal Vein Occlusion therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Retinal Vein Occlusion

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Retinal Vein Occlusion

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Retinal Vein Occlusion pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

3SBio Inc

Allgenesis Biotherapeutics Inc

ANBITION Srl

Annexin Pharmaceuticals AB

AsclepiX Therapeutics Inc

Avirmax Inc

Calpain Therapeutics Pty Ltd

Chengdu Kanghong Pharmaceuticals Group Co Ltd

Drive Therapeutics LLC

EyePoint Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

Graybug Vision Inc

Kala Pharmaceuticals Inc

Kiora Pharmaceuticals Inc

Kodiak Sciences Inc

Luye Pharma Group Ltd

Novartis AG

Novelty Nobility Inc

Ocular Therapeutix Inc

Outlook Therapeutics Inc

Oxular Ltd

Oxurion NV

Ripple therapeutics Corp

Samsung Bioepis Co Ltd

SIFI SpA

Uni-Bio Science Group Ltd

Table of Contents

Table of Contents

Introduction

Global Markets Direct Report Coverage

Retinal Vein Occlusion – Overview

Retinal Vein Occlusion – Therapeutics Development

Retinal Vein Occlusion – Therapeutics Assessment

Retinal Vein Occlusion – Companies Involved in Therapeutics Development

Retinal Vein Occlusion – Drug Profiles

Retinal Vein Occlusion – Dormant Projects

Retinal Vein Occlusion – Discontinued Products

Retinal Vein Occlusion – Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Retinal Vein Occlusion, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021

Products under Development by Companies, 2021 (Contd..1)

Products under Development by Companies, 2021 (Contd..2)

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Retinal Vein Occlusion – Pipeline by 3SBio Inc, 2021

Retinal Vein Occlusion – Pipeline by Allgenesis Biotherapeutics Inc, 2021

Retinal Vein Occlusion – Pipeline by ANBITION Srl, 2021

Retinal Vein Occlusion – Pipeline by Annexin Pharmaceuticals AB, 2021

Retinal Vein Occlusion – Pipeline by AsclepiX Therapeutics Inc, 2021

Retinal Vein Occlusion – Pipeline by Avirmax Inc, 2021

Retinal Vein Occlusion – Pipeline by Calpain Therapeutics Pty Ltd, 2021

Retinal Vein Occlusion – Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2021

Retinal Vein Occlusion – Pipeline by Drive Therapeutics LLC, 2021

Retinal Vein Occlusion – Pipeline by EyePoint Pharmaceuticals Inc, 2021

Retinal Vein Occlusion – Pipeline by F. Hoffmann-La Roche Ltd, 2021

Retinal Vein Occlusion – Pipeline by Graybug Vision Inc, 2021

Retinal Vein Occlusion – Pipeline by Kala Pharmaceuticals Inc, 2021

Retinal Vein Occlusion – Pipeline by Kiora Pharmaceuticals Inc, 2021

Retinal Vein Occlusion – Pipeline by Kodiak Sciences Inc, 2021

Retinal Vein Occlusion – Pipeline by Luye Pharma Group Ltd, 2021

Retinal Vein Occlusion – Pipeline by Novartis AG, 2021

Retinal Vein Occlusion – Pipeline by Novelty Nobility Inc, 2021

Retinal Vein Occlusion – Pipeline by Ocular Therapeutix Inc, 2021

Retinal Vein Occlusion – Pipeline by Outlook Therapeutics Inc, 2021

Retinal Vein Occlusion – Pipeline by Oxular Ltd, 2021

Retinal Vein Occlusion – Pipeline by Oxurion NV, 2021

Retinal Vein Occlusion – Pipeline by Ripple therapeutics Corp, 2021

Retinal Vein Occlusion – Pipeline by Samsung Bioepis Co Ltd, 2021

Retinal Vein Occlusion – Pipeline by SIFI SpA, 2021

Retinal Vein Occlusion – Pipeline by Uni-Bio Science Group Ltd, 2021

Retinal Vein Occlusion – Dormant Projects, 2021

Retinal Vein Occlusion – Dormant Projects, 2021 (Contd..1)

Retinal Vein Occlusion – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Retinal Vein Occlusion, 2021

Number of Products under Development by Companies, 2021

Number of Products by Top 10 Targets, 2021

Number of Products by Stage and Top 10 Targets, 2021

Number of Products by Top 10 Mechanism of Actions, 2021

Number of Products by Stage and Top 10 Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Molecule Types, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2960

Saved reports